ALHC
Bearish signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Alignment Healthcare, Inc.
- Nom
- Alignment Healthcare, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Plans
- Bourse
- NASDAQ
- Capitalisation
- $1.7B
- Employés
- 1,849
- PDG
- John E. Kao
- Site web
- https://www.alignmenthealth.com
- Marché
- CNCELVHUMMOHOSCRUNH
Alignment Healthcare, Inc. is a technology-driven Medicare Advantage provider operating a healthcare platform focused squarely on the consumer. This organization delivers personalized medical services across the United States, primarily for elderly individuals and others requiring specific support, leveraging its suite of Medicare Advantage plans. The company directly owns and operates Medicare Advantage programs in California, North Carolina, and Nevada. Beyond its proprietary offerings, it also orchestrates and furnishes essential healthcare services—including professional, institutional, and supplementary care—for beneficiaries of select plans from unrelated Medicare Advantage Health Maintenance Organizations. Established in 2013, Alignment Healthcare maintains its corporate base in Orange, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 408 781 titres (~5 087 653,31 $ US)
- Insiders
- KONOWIECKI JOSEPH SKAO JOHN E
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$13,712,577
Avg sell (VWAP, 90d window) $12.85 vs last close $8.28 (-35.6%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$11,684,647 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-17
- Liquidity
- Liquid $92,183,973/day · 20d vol
- Last synced
-
2026-10-16 21:10:06
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-06 | Kim Hyong | Sell · S | 32,479 | $8.30 | $269,576 | Form 4 |
| 2026-09-17 | KONOWIECKI JOSEPH S | Sell · S | 23,511 | $8.61 | $202,430 | Form 4 |
| 2026-09-14 | KAO JOHN E | Sell · S · 10b5-1 | 27,400 | $13.00 | $356,200 | Form 4 |
| 2026-09-11 | KAO JOHN E | Sell · S · 10b5-1 | 385,270 | $12.68 | $4,885,224 | Form 4 |
| 2026-09-11 | Maroney Dawn Christine | Sell · S | 122,707 | $12.68 | $1,555,925 | Form 4 |
| 2026-09-10 | KAO JOHN E | Sell · S · 10b5-1 | 172,600 | $12.96 | $2,236,447 | Form 4 |
| 2026-08-14 | Maroney Dawn Christine | Sell · S · 10b5-1 | 5,000 | $14.00 | $70,000 | Form 4 |
| 2026-08-10 | KAO JOHN E | Sell · S · 10b5-1 | 298,000 | $13.88 | $4,136,776 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Despite meaningful operational improvements in 2025, ALHC is overwhelmed by a toxic combination of active securities fraud investigations, aggressive insider selling (~$5.1M), and a new 52-week low, all of which signal…
The first sentence of the analysis written for ALHC on 2026-10-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 1.71 · operating margin 0.4%
Suggested stop 5.69, nearest stored support minus 0.5 ATR(31.3% under the last close). Reward/risk to the next stored resistance is 2.02. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 12.4% | 11.0% | 11.0% | 12.8% | 11.0% | |
| Ebit Margin | 0.4% | -3.9% | -7.0% | -9.1% | -15.2% | |
| Ebitda Margin | 1.1% | -2.9% | -5.8% | -7.9% | -13.9% | |
| Operating Profit Margin | 0.4% | -3.8% | -7.0% | -9.0% | -15.2% | |
| Pretax Profit Margin | -0.0% | -4.7% | -8.1% | -10.4% | -16.7% | |
| Continuous Operations Profit Margin | -0.0% | -4.7% | -8.1% | -10.4% | -16.7% | |
| Net Profit Margin | -0.0% | -4.7% | -8.1% | -10.4% | -16.7% | |
| Bottom Line Profit Margin | -0.0% | -4.7% | -8.1% | -10.4% | -16.7% | |
| Current Ratio | 1.709 | 1.880 | 1.838 | 2.368 | 3.306 | |
| Quick Ratio | 1.709 | 1.880 | 1.838 | 2.368 | 3.306 | |
| Solvency Ratio | 0.034 | -0.148 | -0.291 | -0.335 | -0.552 | |
| Cash Ratio | 1.034 | 1.230 | 0.771 | 1.781 | 2.790 | |
| Price To Earnings Ratio | -5,337.838 | -16.791 | -10.899 | -14.169 | -12.333 | |
| Price To Earnings Growth Ratio | 53.675 | 1.105 | 2.261 | 0.521 | -0.015 | |
| Forward Price To Earnings Growth Ratio | 53.675 | 1.105 | 2.261 | 0.521 | -0.015 | |
| Price To Earnings Diluted Ratio | -5,337.838 | -16.791 | -10.899 | -14.169 | -12.333 | |
| Price To Earnings Diluted Growth Ratio | 53.675 | 1.105 | 2.261 | 0.521 | -0.015 | |
| Price To Book Ratio | 21.813 | 21.496 | 10.216 | 8.949 | 7.900 | |
| Price To Sales Ratio | 0.990 | 0.794 | 0.879 | 1.486 | 2.070 | |
| Price To Free Cash Flow Ratio | 34.563 | -322.868 | -16.845 | -30.795 | -24.890 | |
| Price To Operating Cash Flow Ratio | 27.948 | 61.732 | -27.089 | -46.912 | -30.691 | |
| Debt To Assets Ratio | 0.309 | 0.421 | 0.289 | 0.260 | 0.250 | |
| Debt To Equity Ratio | 1.839 | 3.298 | 1.088 | 0.691 | 0.515 | |
| Debt To Capital Ratio | 0.648 | 0.767 | 0.521 | 0.409 | 0.340 | |
| Long Term Debt To Capital Ratio | 0.643 | 0.763 | 0.508 | 0.403 | 0.330 | |
| Financial Leverage Ratio | 5.945 | 7.832 | 3.771 | 2.662 | 2.061 | |
| Working Capital Turnover Ratio | 11.210 | 10.196 | 6.816 | 4.096 | 4.701 | |
| Operating Cash Flow Ratio | 0.251 | 0.099 | -0.225 | -0.198 | -0.471 | |
| Operating Cash Flow Sales Ratio | 0.035 | 0.013 | -0.032 | -0.032 | -0.067 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.809 | -0.191 | 1.608 | 1.523 | 1.233 | |
| Debt Service Coverage Ratio | 2.867 | -3.129 | -4.959 | -6.226 | -9.277 | |
| Interest Coverage Ratio | 0.934 | -4.313 | -6.020 | -7.034 | -10.209 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 28.688 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.424 | 0.106 | -0.347 | -0.276 | -0.500 | |
| Capital Expenditure Coverage Ratio | 5.225 | 0.839 | -1.644 | -1.911 | -4.291 | |
| Dividend Paid And Capex Coverage Ratio | 5.225 | 0.839 | -1.644 | -1.911 | -4.291 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 80.852 | -26.379 | -14.922 | -16.614 | -13.032 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 12.4% | ▲1.4% | ▲0.7% |
| Ebit Margin | 0.4% | ▲4.2% | ▲7.3% |
| Ebitda Margin | 1.1% | ▲4.0% | ▲7.0% |
| Operating Profit Margin | 0.4% | ▲4.1% | ▲7.3% |
| Pretax Profit Margin | -0.0% | ▲4.7% | ▲8.0% |
| Continuous Operations Profit Margin | -0.0% | ▲4.7% | ▲8.0% |
| Net Profit Margin | -0.0% | ▲4.7% | ▲8.0% |
| Bottom Line Profit Margin | -0.0% | ▲4.7% | ▲8.0% |
| Current Ratio | 1.709 | ▼-0.172 | ▼-0.511 |
| Quick Ratio | 1.709 | ▼-0.172 | ▼-0.511 |
| Solvency Ratio | 0.034 | ▲0.182 | ▲0.292 |
| Cash Ratio | 1.034 | ▼-0.196 | ▼-0.487 |
| Price To Earnings Ratio | -5337.838 | ▼-5321.047 | ▼-4259.432 |
| Price To Earnings Growth Ratio | 53.675 | ▲52.569 | ▲42.165 |
| Forward Price To Earnings Growth Ratio | 53.675 | ▲52.569 | ▲42.165 |
| Price To Earnings Diluted Ratio | -5337.838 | ▼-5321.047 | ▼-4259.432 |
| Price To Earnings Diluted Growth Ratio | 53.675 | ▲52.569 | ▲42.165 |
| Price To Book Ratio | 21.813 | ▲0.317 | ▲7.738 |
| Price To Sales Ratio | 0.990 | ▲0.196 | ▼-0.254 |
| Price To Free Cash Flow Ratio | 34.563 | ▲357.431 | ▲106.730 |
| Price To Operating Cash Flow Ratio | 27.948 | ▼-33.785 | ▲30.950 |
| Debt To Assets Ratio | 0.309 | ▼-0.112 | ▲0.004 |
| Debt To Equity Ratio | 1.839 | ▼-1.459 | ▲0.353 |
| Debt To Capital Ratio | 0.648 | ▼-0.120 | ▲0.111 |
| Long Term Debt To Capital Ratio | 0.643 | ▼-0.120 | ▲0.114 |
| Financial Leverage Ratio | 5.945 | ▼-1.887 | ▲1.491 |
| Working Capital Turnover Ratio | 11.210 | ▲1.014 | ▲3.806 |
| Operating Cash Flow Ratio | 0.251 | ▲0.152 | ▲0.360 |
| Operating Cash Flow Sales Ratio | 0.035 | ▲0.023 | ▲0.052 |
| Free Cash Flow Operating Cash Flow Ratio | 0.809 | ▲1.000 | ▼-0.188 |
| Debt Service Coverage Ratio | 2.868 | ▲5.996 | ▲7.012 |
| Interest Coverage Ratio | 0.934 | ▲5.247 | ▲6.262 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-28.688 | ▼-5.738 |
| Operating Cash Flow Coverage Ratio | 0.424 | ▲0.319 | ▲0.543 |
| Capital Expenditure Coverage Ratio | 5.225 | ▲4.385 | ▲5.581 |
| Dividend Paid And Capex Coverage Ratio | 5.225 | ▲4.385 | ▲5.581 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 80.852 | ▲107.231 | ▲78.871 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.91B | $2.15B | $1.60B | $2.13B | $2.42B | |
| Enterprise value | $3.66B | $2.04B | $1.57B | $1.89B | $2.11B | |
| EV / Sales | 0.93x | 0.76x | 0.86x | 1.31x | 1.81x | |
| EV / Op. cash flow | 26.19x | 58.75x | -26.55x | -41.52x | -26.77x | |
| EV / Free cash flow | 32.39x | -307.29x | -16.51x | -27.26x | -21.71x | |
| EV / EBITDA | 80.85x | -26.38x | -14.92x | -16.61x | -13.03x | |
| Net debt / EBITDA | -5.43x | 1.34x | 0.30x | 2.16x | 1.91x | |
| Current ratio | 1.71x | 1.88x | 1.84x | 2.37x | 3.31x | |
| Income quality | -143.07x | -0.27x | 0.40x | 0.30x | 0.40x | |
| Graham net-net | -$0 | -$0 | -$0 | $0 | $1 | |
| Tax burden | 75.6% | 100.0% | 99.9% | 100.2% | 100.0% | |
| Interest burden | -6.5% | 122.5% | 116.7% | 114.0% | 109.8% | |
| Working capital | $394.7M | $309.8M | $220.5M | $314.6M | $385.6M | |
| Invested capital | $502.6M | $424.1M | $322.5M | $397.9M | $458.9M | |
| Return on assets | -0.1% | -16.4% | -25.0% | -23.6% | -31.0% | |
| Operating ROA | 1.6% | -14.8% | -20.9% | -20.3% | -36.7% | |
| Return on tangible assets | -0.1% | -17.2% | -26.8% | -25.2% | -32.8% | |
| Return on equity | -0.4% | -128.2% | -94.3% | -62.8% | -63.8% | |
| Return on invested capital | 2.9% | -23.5% | -38.9% | -31.8% | -38.4% | |
| Return on capital employed | 2.9% | -23.6% | -38.9% | -31.8% | -38.4% | |
| Earnings yield | -0.0% | -6.0% | -9.2% | -7.0% | -8.1% | |
| Free cash flow yield | 2.9% | -0.3% | -5.9% | -3.2% | -4.0% | |
| Capex / Op. cash flow | 19.1% | 119.1% | -60.8% | -52.3% | -23.3% | |
| Capex / Depreciation | 87.9% | 153.0% | 166.1% | 136.0% | 114.5% | |
| Capex / Sales | 0.7% | 1.5% | 2.0% | 1.7% | 1.6% | |
| SG&A / Sales | 0.0% | 13.7% | 16.9% | 20.6% | 24.9% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.6% | 2.6% | 3.7% | 5.7% | 9.5% | |
| Intangibles / Total assets | 3.4% | 5.0% | 6.8% | 6.4% | 5.6% | |
| Days sales outstanding | 23d | 21d | 24d | 24d | 18d | |
| Days payables outstanding | 44d | 37d | 38d | 50d | 6d | |
| Operating cycle | 23d | 21d | 24d | 24d | 18d | |
| Cash conversion cycle | -20d | -16d | -14d | -27d | 12d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-20 Joseph Konowiecki Sells 23,511 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock Alignment Healthcare, Inc. (NASDAQ: ALHC - Get Free Report) EVP Joseph Konowiecki sold 23,511 shares of Alignment Healthcare stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $8.61, for a total transaction of $202,429.71. Following the completion of the transaction, the executive vice president directly owned
- 2026-09-17 Securities Fraud Investigation Into Alignment Healthcare, Inc. (ALHC) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm LOS ANGELES, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alignment Healthcare, Inc. (“Alignment” or the “Company”) (NASDAQ: ALHC) investors concerning the Company''s possible violations of the federal securities laws.
- 2026-09-17 Alignment Healthcare, Inc. (ALHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
- 2026-09-16 ALHC ALERT: Hagens Berman Updates Investigation of Alignment Healthcare (NASDAQ: ALHC) Following Baird Conference Disclosures SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Hagens Berman is updating its ongoing investigation into Alignment Healthcare, Inc. (NASDAQ: ALHC) on behalf of investors following a nearly 20% stock collapse on Tuesday following management''s disclosures at an analyst conference.
- 2026-09-16 Securities Fraud Investigation Into Alignment Healthcare, Inc. (ALHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Sept. 16, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alignment Healthcare, Inc. (“Alignment” or the “Company”) (NASDAQ: ALHC) on behalf of investors concerning the Company''s possible violations of federal securities laws.
- 2026-09-16 Alignment Healthcare (NASDAQ:ALHC) Reaches New 52-Week Low – What’s Next? Alignment Healthcare, Inc. (NASDAQ: ALHC - Get Free Report) shares reached a new 52-week low during trading on Wednesday. The stock traded as low as $9.94 and last traded at $10.37, with a volume of 28545880 shares trading hands. The stock had previously closed at $12.94. More Alignment Healthcare News Here are the key news
- 2026-09-15 Rosen Law Firm Encourages Alignment Healthcare, Inc. Investors to Inquire About Securities Class Action Investigation - ALHC NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alignment Healthcare, Inc. (NASDAQ: ALHC) resulting from allegations that Alignment Healthcare may have issued materially misleading business information to the investing public. So What: If you purchased Alignment Healthcare securities you may be entitled to compensation without payment of any out of pocket fees or costs throu.
- 2026-09-14 Kaplan Fox Encourages Alignment Healthcare, Inc. (NASDAQ: ALHC) Investors With Losses to Learn More About the Investigation NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (NASDAQ: ALHC).
- 2026-09-13 John Kao Sells 385,270 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock Alignment Healthcare, Inc. (NASDAQ: ALHC - Get Free Report) CEO John Kao sold 385,270 shares of the company''s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $12.68, for a total value of $4,885,223.60. Following the sale, the chief executive officer directly owned 1,223,473 shares of the company''s
- 2026-09-10 Alignment Health''s Fifth Annual Survey Finds Seniors Falling Further Behind: Aging in Place Challenges Continue to Rise as Support Gaps Widen Key indicators worsened in 2026, including aging in place challenges, support gaps, and medical debt Key indicators worsened in 2026, including aging in place challenges, support gaps, and medical debt